Regenerative Surgical Treatment of Peri-implantitis Using Nanobone With or Without Simvastatin

Peri-Implantitis Clinical Trial

— RAS  

Official title:

Regenerative Surgical Treatment of Peri-implantitis Using Nanobone With or Without Simvastatin: A 6-month Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04559841
• Other study ID #: (IEC)/15-2017
• Status: Completed
• Phase: N/A
• Start date: October 6, 2017
• Est. completion date: August 15, 2020

Study information

• Verified date: September 2020
• Source: October 6 University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study was to evaluate the effect of using a synthetic bone substitute with or without simvastatin on regenerative surgical treatment of bone defects associated with peri-implantitis in a 6- months randomized controlled clinical trial.

A total of 30 patients diagnosed with peri-implantitis were randomly assigned to one of two surgical treatment groups (group I: synthetic bone substitute (NanoBone), group II: NanoBone with simvastatin). Clinical measurements included probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), modified sulcus bleeding index (mSBI) and mucosal recession (MR). Radiographic bone fill was evaluated at baseline and after 6- months.

Description:

The study was designed as a prospective single-center, parallel group, 6 month randomized clinical trial evaluating the effect of a bone substitute; NanoBone® (Artoss GmbH, Rostock, Germany) (group 1, control group) compared to the same bone substitute with simvastatin (Corvast 80 mg, Egyphar, Egypt) (group 2, test group) for RST of peri-implantitis. A total of 30 patients suffering from peri-implantitis who needed regenerative treatment of at least one peri-implant bone defect were selected and only one implant per patient (the most severe) was evaluated in the treatment groups. The criteria for diagnosing peri-implantitis is based on the consensus report of the eighth European Workshop on Periodontology [34] ; the presence of a peri-implant marginal bone loss ≥2 mm based on baseline periapical radiographs after delivery of the final restoration and bleeding on probing (BOP) and/or suppuration with or without concomitant deepening of peri-implant pockets.

Clinical and radiographic evaluation were conducted at baseline and 6 months postoperatively. Grouping was done using a random number table generated by a third party. They were numbered according to the order of enrolment and assigned to group I or group II. The grouping results were sealed in an opaque envelope and kept by an independent third party. For each patient, cards opened immediately before the surgical procedures. Treatment assignment in each patient was registered by the clinician who assisted in the operations and kept concealed until the completion of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 15, 2020
• Est. primary completion date: June 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. age > 18 years,

2. having at least one implant demonstrating bone defect =3 mm, which presented a probing depth of =5 mm with BOP and/or suppuration, implants had to be in function for >12 months,

3. no implant mobility and no evidence of occlusal overload,

4. no evidence of occlusal overload

5. presence of at least 2 mm of keratinized attached mucosa .

Exclusion Criteria:

1. serious systemic diseases, medications or conditions that would contraindicate periodontal surgery and compromise wound healing,

2. history of taking systemic antibiotic during the past 3 months,

3. smoking,

4. pregnant or lactating females,

5. implants previously augmented with bone substitute or placed in grafted bone,

6. implants previously treated for peri-implantitis,

7. a mobile implant.

Related Conditions & MeSH terms

• Peri-Implantitis

Intervention

Other:
• bone substitute; NanoBone®
surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.

Locations

Country	Name	City	State
Egypt	October 6 University	El-Sheikh Zayed City	Giza

Sponsors (2)

Lead Sponsor	Collaborator
Reham Lotfy Aggour	October 6 University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical attachment level (CAL)	Clinical attachment level (CAL) defined as probing pocket depth + mucosal recession	6 months
Secondary	probing pocket depth	measured as the distance from the mucosal margin to the base of the deepest pocket of the implant	6 months
Secondary	plaque index (PI)	marked with a score from 0 to 3. Grade 0: no plaque; Grade 1: plaques could be found on the surface of the implant after scratching with the probe tip gently; Grade 2: plaque could be seen by the naked eye; and Grade 3: a large amount of plaques could be seen	6 months
Secondary	Bleeding on probing (BoP)	modified sulcus bleeding index (mSBI) . This index scores the bleeding on a zero to three scale, where 0: no bleeding, 1: isolated bleeding spots, 2: blood forms a confluent red line and 3: heavy or profuse bleeding.	6 months
Secondary	Mucosal recession (MR)	measured as the distance from the mucosal margin and the implant abutment interface	6 months
Secondary	The change in bone level (BL)	the distance (mm) between the implant shoulder and the bottom of the defect	6 months